8-K Announcements
6Material company update
Jun 5, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Feb 23, 2026·SEC
BioNexus Gene Lab Corp.(BGLC)Earnings, Financials & Key Ratios
BGLC•NASDAQ
$2.10
Price updated Jul 6, 2026
AboutBioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.Show more
- Revenue$7M-21.9%
- EBITDA-$3M-110.5%
- Net Income-$3M-86.7%
- EPS (Diluted)-1.61-78.9%
- Gross Margin14.62%+7.8%
- EBITDA Margin-40.27%-169.6%
- Operating Margin-42.54%-157.1%
- Net Margin-40.2%-139.2%
- ROE-35.24%-98.2%
BGLC Price & Volume
BioNexus Gene Lab Corp. (BGLC) stock price & volume — 10-year historical chart
Loading chart...
Catastrophic Revenue Erosion Signals Severe Operational Distress
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and operational viability
Key Thesis Takeaways
- BioNexus Gene Lab Corp.
- faces a critical inflection point characterized by a near-total collapse of its top-line revenue, which plummeted to $22.8K in 2026Q1 from historical quarterly averages exceeding $2.0M.
- The company's inability to maintain positive gross margins, which hit -99.5% in the most recent quarter, suggests a fundamental failure in its diagnostic business model and pricing power.
- Investors should remain cautious as the firm continues to burn through its $4.0M cash position while struggling with an accumulated deficit of -$7.0M, indicating significant long-term viability risks.
Verdict Logic
the company's core business model appears to be failing, evidenced by the collapse of quarterly revenue to $22.8K and a persistent inability to generate sustainable free cash flow.
BGLC Growth Metrics
BioNexus Gene Lab Corp. (BGLC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-8.2%
3 Years-12.09%
TTM-42.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-37.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-25.42%
Return on Capital
10 Years-35.16%
5 Years-14.89%
3 Years-28.46%
Last Year-36.7%
BGLC Recent Earnings
BioNexus Gene Lab Corp. (BGLC) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.23
—
Rev
$22,842
—
Q2 2026
Apr 14, 2026Metric
Actual
Est
EPS
$0.53
—
Rev
$483,760
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.39
—
Rev
$3M
—
Q3 2025
Aug 18, 2025Metric
Actual
Est
EPS
$0.34
—
Rev
$2M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.23 | $22,842 |
| Q2 2026 | Apr 14, 2026 | $0.53 | $483,760 |
| Q4 2025 | Nov 14, 2025 | $0.39 | $3M |
| Q3 2025 | Aug 18, 2025 | $0.34 | $2M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for BioNexus Gene Lab Corp. (BGLC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.10 | $4.22M | -1.30 | -21.93% | -40.2% | -35.24% | — | |
| $18.00 | $1.23B | -1.08 | -1.89% | -45.57% | -56.31% | — | |
| $5.06 | $2.62B | -29.76 | 40.34% | -2.58% | -17.08% | — | |
| $7.53 | $7.16M | -0.14 | — | — | -99.39% | — | |
| $7.24 | $90.45M | -28.96 | 14.52% | -9.05% | -70.95% | — | |
| $564.98 | $44.87B | 43.19 | 10.42% | 24.63% | 70.87% | — |
Compare BGLC vs Peers
BioNexus Gene Lab Corp. (BGLC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BGLC SEC Filings & Documents
BioNexus Gene Lab Corp. (BGLC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BGLC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BGLC Frequently Asked Questions
BioNexus Gene Lab Corp. (BGLC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is BioNexus Gene Lab Corp.'s revenue?
BioNexus Gene Lab Corp. (BGLC) reported $5.3M in revenue for fiscal year 2025.
How fast is BioNexus Gene Lab Corp. growing?
BioNexus Gene Lab Corp. (BGLC) saw revenue decline by 21.9% over the past year.
Is BGLC profitable?
BioNexus Gene Lab Corp. (BGLC) reported a net loss of $2.9M for fiscal year 2025.
Dividend & Returns
What is BGLC's return on equity?
BioNexus Gene Lab Corp. (BGLC) has a return on equity (ROE) of -35.2%. Negative ROE indicates the company is unprofitable.
What is BioNexus Gene Lab Corp.'s free cash flow?
BioNexus Gene Lab Corp. (BGLC) had negative free cash flow of $1.2M in fiscal year 2025, likely due to heavy capital investments.